CVRx

CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. It has developed the second generation Barostim neo, an implantable system designed to treat heart failure and hypertension. It operates through the following geographical segments: United States, Germany, and Other Countries. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2000 and is headquartered in Minneapolis, MN.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVRx reports stellar Q4 results, eyes growth opportunities in 2023

CVRx's strong performance in 2022, highlighted by revenue growth and operational advancements, sets a positive trajectory for the company. While challenges persist in European market expansion, the focus on key growth areas and strategic initiatives positions CVRx for continued success in 2023.

CVRx reports stellar Q1 performance, eyes label expansions for growth

CVRx's Q1 2023 showcased robust revenue growth, operational progress, and increased guidance for the full year. While challenges like rising expenses and inventory management exist, the company's focus on profitability, label expansions, and market expansion programs position it well for future success.

CVRx excels in Q2 with robust revenue growth and market expansion

CVRx's strong Q2 performance, revenue growth, and strategic initiatives position the company for future success in the heart failure market.
While facing challenges in clinical trial enrollment and regulatory uncertainties, CVRx's focus on market expansion and pricing optimization presents opportunities for sustained growth.
With a clear roadmap for revenue improvement, cash flow optimization, and market penetration, CVRx is poised to capitalize on the growing demand for its therapies.

CVRx reports robust Q3 performance, raises full-year revenue guidance

CVRx delivered a strong performance in Q3 2023, marked by revenue growth and operational advancements.
While facing challenges like net losses and regulatory uncertainties, the company is well-positioned for future growth.
Opportunities lie in market expansion, revenue growth, and maintaining operational efficiencies for sustained success.

CVRx posts robust Q4 earnings, eyes growth amid leadership transition

CVRx reported strong financial performance in Q4 2023, with significant revenue growth and operational achievements.
The company faces challenges in managing expenses, designing new clinical studies, and balancing growth strategies.
Opportunities lie in expanding market opportunities, engaging stakeholders for new programs, and pursuing aggressive growth strategies.
Guidance for 2024 indicates a positive outlook with revenue projections and strategic focus on growth and operational efficiency.

CVRx reports revenue growth in Q1, focuses on therapy adoption

CVRx's Q1 performance showed revenue growth but faced challenges from disruptions and increased expenses.
Strengthening market development efforts and therapy adoption are key focus areas for CVRx.
Opportunities lie in improving awareness, evidence, and access for Barostim therapy.
Navigating challenges like sales turnover and market dynamics will be crucial for CVRx's growth.

CVRx reports strong revenue growth and strategic leadership enhancements

CVRx's Q2 2024 performance showed revenue growth and strategic leadership enhancements.
While challenges like increased expenses and net losses persist, opportunities for revenue growth exist.
The company's focus on market advocacy and product development positions it for future success.

CVRx reports revenue growth and strategic focus amidst rising expenses

CVRx shows revenue growth and positive therapy outcomes but faces challenges in managing expenses. The company's financial position remains stable with a focus on strategic growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It operates through the United States, Germany, and Other Countries geographical segments. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2001 and is headquartered in Minneapolis, MN.

CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in CVRx (CVRX): Can Its 19.0% Jump Turn into More Strength?

MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced the appointment of Robert John as Chief Revenue Officer effective June 27. In this role, John will lead the Company's US sales team with the objective of maximizing the positive impact of Barostim therapy on patients suffering from heart failure and establishing Barostim as standard of care in the United States.

CVRx Announces Appointment of Robert Allen John as Chief Revenue Officer

NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ:CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRX

CVRx (CVRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CVRx (CVRX) Stock Jumps 33.9%: Will It Continue to Soar?

MINNEAPOLIS, May 22, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5, 2024. The Company is scheduled to present at 8:40am Central Time the same day via webcast.

CVRx to Present at the William Blair 44th Annual Growth Stock Conference

MINNEAPOLIS, May 16, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced three additions to its senior leadership team. Philip B. Adamson, MD, MSc, FACC, FESC, FRCP (Ed) has been appointed as Chief Medical Officer, Bonnie Handke, RN, MBA will assume the role of Senior Vice President of Patient Access, Reimbursement, and Healthcare Economics, and Jennifer E. Englund recently joined as Senior Vice President of Global Clinical Affairs. These roles will focus on driving the adoption of the company's Barostim™ therapy and expanding patient access.

CVRx Announces Key Senior Leadership Team Hires

CVRx (NASDAQ: CVRX ) stock is falling hard on Wednesday after posting results from its earnings report for the first quarter of 2024. The bad news for investors in CVRX stock starts with its earnings per share of 0$1.04.

Why Is CVRx (CVRX) Stock Down 32% Today?

CVRx, Inc. (NASDAQ:CVRX ) Q1 2024 Earnings Conference Call April 30, 2024 5:00 PM ET Company Participants Mike Vallie - IR Kevin Hykes - President and CEO Jared Oasheim - CFO Conference Call Participants Lilia-Celine Lozada - JPMorgan Phillip Dantoin - Piper Sandler Margaret Kaczor - William Blair Bill Plovanic - Canaccord Frank Takkinen - Lake Street Capital Markets Chase Knickerbocker - Craig-Hallum Operator Greetings, and welcome to the CVRx Q1 2024 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.

CVRx, Inc. (CVRX) Q1 2024 Earnings Call Transcript

MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2024.

CVRx Reports First Quarter 2024 Financial and Operating Results

CVRx's (CVRX) announcement of the availability of additional data supporting the long-term benefits of Barostim is likely to lead to improved patient care.

CVRx's (CVRX) Latest Data Favors Barostim's Long-Term Benefits

MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release first quarter 2024 financial and operating results after market close on Tuesday, April 30th, 2024. The Company will host a conference call to review its results at 5:00pm Eastern Time the same day.

CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024

BeAT-HF trial data published in the European Journal of Heart Failure and new abstracts presented at THT conference

CVRx announces availability of additional data supporting long-term benefits of Barostim

MINNEAPOLIS, Jan. 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc . (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today the appointment of Kevin Hykes as the Company's new President and Chief Executive Officer, effective February 12. Hykes will continue to serve on the Company's Board of Directors. Yared will retire from the Company and resign his Board seat concurrent with Hykes' appointment and has agreed to consult with the Company to ensure a seamless transition.

CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer

Eldorado Gold

Warrior Met Coal

Potbelly

World Acceptance

HCC, EGO, WRLD, PBPB and CVRX have been added to the Zacks Rank #1 (Strong Buy) List on January 30, 2024.

New Strong Buy Stocks for January 30th

CVRx, Inc. (CVRX) Q4 2023 Earnings Call Transcript

CVRx (CVRX) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.51 per share a year ago.

CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates

MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2023, and affirmed its 2024 business outlook.

CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

CVRx (CVRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CVRx (CVRX) Upgraded to Strong Buy: What Does It Mean for the Stock?

MINNEAPOLIS, Jan. 11, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2023 financial and operating results after market close on Thursday, January 25th, 2024. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.

CVRx to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call on January 25th, 2024

CVRx (CVRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

What Makes CVRx (CVRX) a Good Fit for 'Trend Investing'

MINNEAPOLIS, Dec. 27, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024. The Company is scheduled to present at 3:45pm Pacific Time the same day via webcast.

CVRx to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CVRx (CVRX) Moves 24.2% Higher: Will This Strength Last?

U.S. annual market opportunity increases based on real world adoption and strength of long-term BeAT-HF data U.S. annual market opportunity increases based on real world adoption and strength of long-term BeAT-HF data

CVRx receives FDA approval for expanded labeling of Barostim

Here's Why 'Trend' Investors Would Love Betting on CVRx (CVRX)

Does CVRx (CVRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

News for CVRx Stock (CVRX)